TABLE 3.

Patients with baseline isolates who presented clinical failure or had an indeterminate status at TOC^a

Arm and pathogen	Country	Infection type	CAZ-AVI MIC (μg/ml)	Molecular characterization
CAZ-AVI
K. pneumoniae	Bulgaria	cUTI	0.5	CTX-M-15; SHV-1
P. aeruginosa	Bulgaria	cUTI	16	OXA-2; OXA-74; PER-1
E. coli	Croatia	cUTI	0.12	CTX-M-15
P. mirabilis	Croatia	cUTI	0.06	CMY-16
E. coli	Israel	cUTI	0.5	CTX-M-15; OXA-1
E. coli	Romania	cUTI	0.12	CTX-M-15; TEM-1
P. mirabilis	Romania	cUTI	0.5	ACC-4; TEM-1
E. cloacae/K. pneumoniae	Russia	cIAI	1/0.25	cAmpC/CTX-M-15; OXA-1; SHV-1; TEM-1
E. coli	Russia	cIAI	0.12	CTX-M-15; TEM-1
E. coli	Russia	cUTI	0.25	CTX-M-15; OXA-1
E. coli	South Africa	cUTI	0.12	CTX-M-15; OXA-1
E. cloacae	Ukraine	cUTI	0.25	CTX-M-15; cAmpC
E. coli	Ukraine	cUTI	0.06	CTX-M-15; TEM-1
P. aeruginosa	Ukraine	cUTI	64	OXA-10; VEB-1
BAT
K. pneumoniae	Argentina	cUTI	NA	KPC-2; SHV-11; TEM-1
E. coli	Bulgaria	cIAI	NA	CTX-M-15; OXA-1
K. pneumoniae	Bulgaria	cUTI	NA	SHV-11; TEM-1; VIM-4
E. cloacae	Croatia	cUTI	NA	CTX-M-15; cAmpC; OXA-1; TEM-1
E. cloacae	Israel	cIAI	NA	CTX-M-15; OXA-1
E. coli	Israel	cIAI	NA	CTX-M-15; OXA-1
E. coli	Israel	cUTI	NA	CTX-M-15; OXA-1
K. pneumoniae	Romania	cUTI	NA	CTX-M-15; OXA-1; SHV-1
E. coli	Russia	cIAI	NA	CTX-M-15; OXA-1
K. pneumoniae	Russia	cIAI	NA	OXA-2; SHV-18
E. coli	Spain	cUTI	NA	CTX-M-27
E. coli	Turkey	cUTI	NA	CTX-M-15; TEM-1
K. pneumoniae	Ukraine	cUTI	NA	CMY-4; CTX-M-15; SHV-1

^aTOC, test of cure; CAZ-AVI, ceftazidime-avibactam; BAT, best available therapy; cUTI, complicated urinary tract infection; cIAI, complicated intra-abdominal infection; NA, not available. cAmpC represents overexpression of the intrinsic chromosomal ampC gene according to qRT-PCR experiments.